Comfrey

A traditional botanical historically used in topical preparations; modern discussions often emphasize safety context and preparation differences.

Last reviewed: February 6, 2026

Overview

Comfrey (Symphytum species) is a deep-rooted perennial plant native to Europe and parts of western Asia, and one of the more historically prominent botanical names in European folk-medicine traditions. Its common names — including "knitbone" and "boneset" in English — reflect longstanding folk associations with topical comfort applications, particularly in poultice and compress preparations. Comfrey is also one of the botanical ingredients most frequently cited in modern safety discussions, owing to the presence of pyrrolizidine alkaloids (PAs) in the plant — a class of compounds that has prompted regulatory restrictions and usage warnings in multiple countries.

This page provides educational context on comfrey's historical background, safety landscape, and the factors that shape contemporary discussions around it. It does not recommend use for any condition.

What it is

Comfrey encompasses several species within the Symphytum genus, with Symphytum officinale (common comfrey) and Symphytum × uplandicum (Russian comfrey, a hybrid) being the most frequently referenced in both traditional and commercial contexts. The plant is characterized by large, hairy leaves and a substantial taproot, and it has a long history of cultivation in European gardens. In the contemporary market, comfrey appears in:

historical herbal texts
topical herbal products in some markets

The defining feature of comfrey from a modern safety standpoint is its content of pyrrolizidine alkaloids — a group of naturally occurring hepatotoxic compounds found in varying concentrations across different plant parts, species, and growing conditions. The root typically contains higher PA concentrations than the leaves, and different Symphytum species carry different PA profiles. This variability is a central factor in how comfrey products are discussed, regulated, and labeled across jurisdictions.

Traditional use (educational)

Comfrey's presence in European herbal literature stretches back at least to the Middle Ages, with references appearing in texts by Dioscorides, Paracelsus, and later herbalists including Nicholas Culpeper and John Gerard. The common name "knitbone" reflects a centuries-old folk association with topical applications involving bone and joint comfort narratives — a tradition that persisted in rural European and British folk practice well into the 20th century. Traditional references often describe comfrey in relation to:

topical herbal applications for comfort
recovery-oriented folk practices
herbal poultice traditions

These descriptions reflect historical usage patterns rooted in observational folk tradition and should not be interpreted as clinical evidence. The traditional emphasis on topical rather than internal use is notable, as the safety considerations that dominate modern comfrey discussions relate primarily — though not exclusively — to internal consumption. The relationship between traditional topical practice and the modern safety landscape is a nuanced one, shaped by evolving knowledge of PA chemistry and toxicology.

What research says

The research landscape for comfrey is dominated by safety and toxicology considerations rather than efficacy research. Published studies on pyrrolizidine alkaloids — including those found in comfrey — have documented hepatotoxic, genotoxic, and potentially carcinogenic properties in animal models and, in some cases, human case reports. These findings have been the primary driver behind regulatory actions in multiple countries, including restrictions on oral comfrey products in the United States, United Kingdom, Germany, and elsewhere.

A smaller body of research has examined topical comfrey preparations — particularly PA-reduced or PA-free formulations — in the context of musculoskeletal comfort outcomes, with some clinical trials conducted primarily in European settings. The methodological quality, sample sizes, and product specifications across these studies vary, and the applicability of findings for one specific proprietary preparation to comfrey products in general is a recognized limitation in the literature. The tension between comfrey's long traditional history and the seriousness of its PA-related safety concerns is a defining feature of the contemporary discussion, and most authoritative references prioritize the safety dimension.

Safety & interactions

Safety is the dominant theme in modern educational and regulatory discussions about comfrey, and the pyrrolizidine alkaloid content of the plant is the central concern. Key themes in reference literature include:

concern about pyrrolizidine alkaloids (PAs), particularly with internal use
topical use discussions may still include caution, especially for prolonged use or broken skin
product labeling and PA-free claims can vary and require careful evaluation

PA-related liver toxicity — including veno-occlusive disease — is documented in medical case literature, predominantly in association with oral ingestion of comfrey-containing products or PA-contaminated herbal preparations. The severity and irreversibility of documented hepatic outcomes are the basis for regulatory restrictions on internal comfrey products in many jurisdictions. For topical products, the safety discussion is more nuanced: systemic PA absorption through intact skin is considered lower than through oral routes, but the extent of transdermal absorption and the implications of prolonged or repeated topical exposure remain subjects of ongoing evaluation in toxicological literature.

Who should be cautious

Educational and regulatory safety references consistently identify several populations as warranting particular awareness regarding comfrey products:

pregnant or breastfeeding individuals
people with liver disease or liver-related concerns
children
anyone considering internal use of comfrey products

The regulatory stance in many countries effectively extends caution beyond specific populations to the general public for oral comfrey products — internal use is restricted or prohibited in several jurisdictions specifically because of PA-related hepatotoxicity concerns. For topical products, the cautionary landscape is more variable and depends on the product's PA content, labeling claims, and the regulatory framework of the market in which it is sold. Professional consultation is a consistent theme across conventional health sources for anyone with questions about comfrey-containing products in any form.

Quality & sourcing considerations

Quality assessment for comfrey products is inseparable from the PA safety question, and several variables are central to the discussion:

PA content and testing claims
clear labeling and formulation transparency
reputable sourcing and third-party verification where available

Products marketed as "PA-free" or "PA-reduced" vary in the rigor of their testing and the thresholds they apply, and these claims are not subject to uniform regulatory definition across all markets. The Symphytum species used, the plant part (root versus leaf), the extraction or processing method, and the analytical testing protocol all influence the PA content of a final product — and not all of these variables are transparently communicated on product labels. In jurisdictions where topical comfrey products remain available, third-party PA testing, clear species identification, and detailed processing information are frequently cited as quality indicators in educational sourcing literature.

FAQs

Why is comfrey often discussed with safety cautions? Modern references focus on compounds that may pose risk, especially with internal use.
Are all comfrey products the same? No—composition and labeling can differ widely.
Is this page recommending comfrey? No—this is educational information only.